bearish
Jiangsu Hengrui Medicine (600276.CH) 23H1 - Has the Turning Point of Performance Really Arrived?
436 Views22 Aug 2023 08:55
We do not deny that Hengrui's low point was in 2022, but VBP and anti-corruption would delay the arrival of performance turning point. 23Q2 performance rebound is not convincing. Hengrui is overvalued
SUMMARY
(Sign Up to Access)Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 3-minute read)
Discussions
(Paid Plans Only)
Top 5%
Xinyao (Criss) Wang
HK/China Healthcare Analyst (ex-Fosun Pharma)
- Pre-IPO Malo Medical Management - Profit Model Is Not Mature; Future Expansion Is Worrying04 Oct 2023
- MedSci Healthcare Holdings (2415.HK) - Lack of Control over Core Resources Is a Critical Pain Point28 Sep 2023
- Remegen (9995.HK/688331.CH) 23H1 - This Is Why RemeGen’s Commercialization Performance Is so Weak24 Aug 2023
- Jiangsu Hengrui Medicine (600276.CH) 23H1 - Has the Turning Point of Performance Really Arrived?22 Aug 2023
- Pre-IPO WuXi XDC - The Beautiful Story and the Truth Behind17 Jul 2023
- Jiangsu Hengrui Medicine (600276.CH) 2022/23Q1 - The Situation Is Not as Optimistic as Imagined24 Apr 2023
- Jiangsu Hengrui Medicine (600276.CH) - About The Performance Recovery and the Concerns Behind04 Jan 2023
x